Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?

ABSTRACT:

Objectives

We critically evaluated the quality of evidence and quality of harm reporting in clinical trials that evaluated the effectiveness of hydroxychloroquine (HCQ) or chloroquine (CQ) for the treatment of coronavirus disease 2019 (COVID-19).

Study design and setting

Scientific databases were systematically searched to identify relevant trials of HCQ/CQ for the treatment of COVID-19 published up to 10 September 2020. The Cochrane risk-of-bias tools for randomized trials and non-randomized trials of interventions were used to assess risk of bias in the included studies. A 10-item Consolidated Standards of Reporting Trials (CONSORT) harm extension was used to assess quality of harm reporting in the included trials.

Results

Sixteen trials, including fourteen randomiz

SUBMITTER: Mazhar F 

PROVIDER: S-EPMC7524513 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature